Aris Polyzos

1.9k total citations
55 papers, 1.5k citations indexed

About

Aris Polyzos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Aris Polyzos has authored 55 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Aris Polyzos's work include Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Treatment and Pharmacology (12 papers). Aris Polyzos is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Treatment and Pharmacology (12 papers). Aris Polyzos collaborates with scholars based in Greece, United States and United Kingdom. Aris Polyzos's co-authors include Vassilis Georgoulias, George Samonis, Nikolaos Ziras, Stylianos Kakolyris, K. Syrigos, John Souglakos, Nikolaos Androulakis, Ch. Kouroussis, L. Vamvakas and Αthanasios Kotsakis and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Cancer Letters.

In The Last Decade

Aris Polyzos

54 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aris Polyzos Greece	19	1.2k	607	267	262	229	55	1.5k
Nikolaos Ziras Greece	17	996 0.8×	369 0.6×	207 0.8×	304 1.2×	150 0.7×	55	1.2k
Ch. Kouroussis Greece	23	1.4k 1.1×	621 1.0×	187 0.7×	392 1.5×	275 1.2×	54	1.6k
B. Mirtsching United States	12	1.1k 1.0×	459 0.8×	131 0.5×	288 1.1×	182 0.8×	27	1.3k
Stacey Stein United States	18	802 0.7×	387 0.6×	260 1.0×	327 1.2×	315 1.4×	74	1.4k
N. Androulakis Greece	20	1.1k 0.9×	681 1.1×	182 0.7×	290 1.1×	236 1.0×	46	1.3k
Olivier Dubreuil France	15	932 0.8×	498 0.8×	378 1.4×	382 1.5×	310 1.4×	56	1.6k
Silvia Mezi Italy	15	1.0k 0.9×	416 0.7×	240 0.9×	201 0.8×	252 1.1×	51	1.4k
A. Kalykaki Greece	16	934 0.8×	387 0.6×	126 0.5×	329 1.3×	218 1.0×	52	1.2k
Louise C. Connell United States	8	1.2k 1.0×	347 0.6×	211 0.8×	107 0.4×	242 1.1×	31	1.6k
Richard Létourneau Canada	11	764 0.6×	280 0.5×	157 0.6×	286 1.1×	210 0.9×	26	1.0k

Countries citing papers authored by Aris Polyzos

Since Specialization

Citations

This map shows the geographic impact of Aris Polyzos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aris Polyzos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aris Polyzos more than expected).

Fields of papers citing papers by Aris Polyzos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aris Polyzos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aris Polyzos. The network helps show where Aris Polyzos may publish in the future.

Co-authorship network of co-authors of Aris Polyzos

This figure shows the co-authorship network connecting the top 25 collaborators of Aris Polyzos. A scholar is included among the top collaborators of Aris Polyzos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aris Polyzos. Aris Polyzos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Syrios, John, Charalambos Kouroussis, Αthanasios Kotsakis, et al.. (2019). Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. PubMed. 71(3). 182–190. 2 indexed citations

Saloustros, Emmanouil, Michail Nikolaou, K. Kalbakis, et al.. (2017). Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. Clinical Breast Cancer. 18(1). 88–94. 17 indexed citations

Economopoulou, Panagiota, Leonidas Chelis, Aris Polyzos, et al.. (2016). Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Clinical & Translational Oncology. 19(3). 317–325. 7 indexed citations

Kotsakis, Αthanasios, Nikolaos Kentepozidis, Christos Emmanouilidis, et al.. (2015). Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). Lung Cancer. 88(1). 57–62. 5 indexed citations

Vamvakas, Lambros, Alexios Matikas, Athanasios Karampeazis, et al.. (2014). Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). BMC Cancer. 14(1). 277–277. 14 indexed citations

Boukovinas, Ioannis, Nikolaos Xenidis, Pavlos Papakotoulas, et al.. (2013). A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. The Breast. 22(6). 1171–1177. 9 indexed citations

Boukovinas, Ioannis, Nikolaos Androulakis, Nikolaos Kentepozidis, et al.. (2011). Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology. 69(2). 351–356. 4 indexed citations

Karachaliou, Niki, Aris Polyzos, Nikolaos Kentepozidis, et al.. (2010). A Multicenter Phase II Trial with Irinotecan plus Oxaliplatin as First-Line Treatment for Inoperable/Metastatic Cancer of the Biliary Tract. Oncology. 78(5-6). 356–360. 14 indexed citations

Grapsa, Dimitra, et al.. (2009). Ascitic Fluid Cytology of Yolk Sac Tumor of the Ovary. Acta Cytologica. 53(6). 701–703. 3 indexed citations

10.

Pallis, Athanasios, Aris Polyzos, Ioannis Boukovinas, et al.. (2008). Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience. Journal of Thoracic Oncology. 3(5). 505–510. 24 indexed citations

11.

Kakolyris, Stylianos, John Souglakos, Aris Polyzos, et al.. (2008). Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy. Oncology. 74(1-2). 31–36. 4 indexed citations

12.

Agelaki, Sofia, Nikolaos Androulakis, Athina Agelidou, et al.. (2007). P2-159: Phase III randomized study of oral vinorelbine (oV) and gemcitabine (G) (oVG) versus docetaxel (D) and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): A preliminary report. Journal of Thoracic Oncology. 2(8). S632–S632. 2 indexed citations

13.

Androulakis, Nikolaos, Gerasimos Aravantinos, Kostas Syrigos, et al.. (2006). Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma. Oncology. 70(4). 280–284. 20 indexed citations

14.

Ignatiadis, Michail, Aris Polyzos, George P. Stathopoulos, et al.. (2006). A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer. Oncology. 71(3-4). 159–163. 39 indexed citations

15.

Souglakos, John, N. Androulakis, K. Syrigos, et al.. (2006). FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). British Journal of Cancer. 94(6). 798–805. 277 indexed citations

16.

Mavroudis, D., Nikolaos Malamos, Aris Polyzos, et al.. (2004). Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study. Oncology. 67(3-4). 250–256. 24 indexed citations

17.

Tsavaris, Nikolas, Christos Kosmas, Aris Polyzos, et al.. (2004). Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer. Investigational New Drugs. 22(2). 193–198. 82 indexed citations

18.

Tsavaris, Νicolas, Aris Polyzos, Christos Kosmas, et al.. (2002). Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination. Chemotherapy. 48(2). 94–99. 15 indexed citations

19.

Nikou, George, et al.. (2001). The significance of the early detection of clinical symptoms in the overall survival of patients with pancreatic cancer. Annals of Gastroenterology. 14(1). 3 indexed citations

20.

Veslemes, M., Aris Polyzos, P. Latsi, et al.. (1998). Optimal Duration of Chemotherapy in Small Cell Lung Cancer: A Randomized Study of 4 versus 6 Cycles of Cisplatin-Etoposide. Journal of Chemotherapy. 10(2). 136–140. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact